Article
Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.
Nature communications - 6 Sept 2021
Hwang Michael S, Miller Michelle S, Thirawatananond Puchong, Douglass Jacqueline, Wright Katharine M, Hsiue Emily Han-Chung, Mog Brian J, Aytenfisu Tihitina Y, Murphy Michael B, Aitana Azurmendi P, Skora Andrew D, Pearlman Alexander H, Paul Suman, DiNapoli Sarah R, Konig Maximilian F, Bettegowda Chetan, Pardoll Drew M, Papadopoulos Nickolas, Kinzler Kenneth W, Vogelstein Bert, Zhou Shibin, Gabelli Sandra B
Abstract excerpt
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of human cancers. One major challenge precluding the wider implementation of CAR therapy is the paucity of tumor-specific antigens. Here, we describe the development of a CAR targeting the tumor-specific isocitrate dehydrogenase 2 (IDH2) with R140Q mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.